Cue biopharma announces chief medical officer transition

Boston, jan. 23, 2023 (globe newswire) --  cue biopharma, inc. (nasdaq: cue), a clinical-stage biopharmaceutical company developing a novel class of injectable biologics to selectively engage and modulate disease-specific t cells directly within the patient's body, announced today that matteo levisetti, m.d., senior vice president (svp) of clinical development at cue biopharma, has been promoted to chief medical officer (cmo) effective january 17, 2023. current acting cmo kenneth pienta, m.d., has transitioned from his current role and will serve as a clinical advisor to the company effective as of the same date.
CUE Ratings Summary
CUE Quant Ranking